TIE receptor

TIE receptor. The TIE receptors, comprising TIE1 and TIE2 (also known as TEK), are a family of receptor tyrosine kinases predominantly expressed on endothelial cells and critical for vascular development and homeostasis. Their discovery, stemming from research at institutions like the Ludwig Institute for Cancer Research, revealed a unique extracellular region containing immunoglobulin-like domains, epidermal growth factor-like domains, and fibronectin type III domains. Signaling is primarily initiated by angiopoietin ligands, orchestrating complex pathways essential for blood vessel stability, lymphangiogenesis, and the inflammatory response.

Structure and isoforms

The TIE receptors are type I transmembrane proteins characterized by a distinctive extracellular domain architecture. This region includes two immunoglobulin-like domains at the N-terminus, followed by three epidermal growth factor-like domains, and a third immunoglobulin-like domain proximal to the cell membrane. The intracellular portion contains a split tyrosine kinase domain. While TIE1 is considered an orphan receptor, TIE2 is the primary signaling receptor binding angiopoietin-1 (ANGPT1) and angiopoietin-2 (ANGPT2). Alternative splicing can generate isoforms, particularly for TIE1, which may influence interactions with co-receptors or modulate signaling output. Structural studies, including those utilizing X-ray crystallography, have detailed the binding interface between TIE2 and its ligands, revealing critical interactions for signal transduction.

Ligands and signaling pathways

The canonical ligands for the TIE receptors are the angiopoietins, with ANGPT1 acting as the primary agonist for TIE2, promoting receptor autophosphorylation and downstream signaling. ANGPT2, often context-dependent, can act as a competitive antagonist in the presence of ANGPT1 or a weak agonist under certain conditions. Upon ligand binding and dimerization, activated TIE2 recruits adaptor proteins such as GRB2 and p85 subunit of PI3K, initiating major pathways including the PI3K/AKT/mTOR pathway and the MAPK/ERK pathway. These cascades regulate processes like cell survival, cell migration, and cell adhesion. TIE1 can modulate TIE2 signaling through heterodimer formation, and cross-talk with other pathways like VEGF signaling is crucial for integrated vascular control.

Physiological functions

TIE receptor signaling is indispensable for normal embryogenesis, particularly in the later stages of vascular development following initial vasculogenesis driven by VEGF. The ANGPT1-TIE2 axis is vital for promoting vascular stability, pericyte recruitment, and endothelial cell quiescence in mature vessels. In the lymphatic system, this signaling is essential for lymphangiogenesis, as demonstrated in models like the Chy mouse. Furthermore, TIE receptors regulate inflammatory response by controlling vascular permeability and leukocyte adhesion, with TIE2 expression on a subset of macrophages, known as TIE2-expressing monocytes, playing a role in tumor angiogenesis and tissue repair.

Role in disease

Dysregulation of TIE receptor signaling is implicated in numerous pathological conditions. In cancer, aberrant expression of ANGPT2 and imbalanced ANGPT1/ANGPT2 ratios contribute to the chaotic, leaky tumor vasculature characteristic of solid tumors, facilitating metastasis. Germline mutations in the TEK gene cause inherited venous malformations, such as those seen in Familial Cutaneous and Mucosal Venous Malformations. The pathway is also central to diabetic retinopathy, age-related macular degeneration, and atherosclerosis, where disrupted endothelial stability promotes neovascularization and plaque instability. In sepsis and acute lung injury, loss of protective TIE2 signaling exacerbates vascular leakage and organ dysfunction.

Therapeutic targeting

Given their pivotal role in vascular pathologies, TIE receptors are attractive therapeutic targets. Strategies include monoclonal antibodies against ANGPT2, such as nesvacumab, and recombinant protein forms of ANGPT1 or engineered TIE2 agonists like Vasculotide. Small molecule tyrosine kinase inhibitors targeting the TIE2 kinase domain, often multi-targeted agents like cabozantinib and regorafenib approved for renal cell carcinoma and hepatocellular carcinoma, are in clinical use. Gene therapy approaches aim to restore balanced signaling in vascular malformations. Ongoing clinical trials, including those sponsored by Regeneron Pharmaceuticals and GlaxoSmithKline, continue to evaluate the efficacy and safety of modulating this pathway in oncology and ophthalmology.

Category:Receptor tyrosine kinases Category:Angiogenesis Category:Cell signaling